

Filed: July 13, 2018

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC.
Petitioner,

v.

BIOGEN MA, INC.
Patent Owner.

Patent No. 8,399,514

Inter Partes Review IPR2018-01403

**PETITION FOR *INTER PARTES* REVIEW OF
U.S. PATENT NO. 8,399,514**

TABLE OF CONTENTS

	Page
I. INTRODUCTION	1
II. MANDATORY NOTICES	1
A. Real Parties-In-Interest (37 C.F.R. § 42.8 (b)(1)).....	1
B. Related Matters (37 C.F.R. § 42.8(b)(2)).....	1
C. Identification of Counsel (37 C.F.R. § 42.8(b)(3))	3
D. Service Information (37 C.F.R. § 42.8(b)(4))	4
III. GROUNDS FOR STANDING (37 C.F.R. § 42.101 AND 42.104)	4
IV. IDENTIFICATION OF CHALLENGE AND STATEMENT OF THE PRECISE RELIEF REQUESTED (37 C.F.R. § 42.22(a) and 37 C.F.R. § 42.104(b)).....	4
V. THRESHOLD REQUIREMENT FOR INTER PARTES REVIEW	6
VI. STATEMENT OF REASONS FOR RELIEF REQUESTED	6
A. Summary of the Argument.....	6
B. Level of Ordinary Skill in the Art	10
C. The '514 Patent and its Prosecution.....	11
1. The Treatment of Multiple Sclerosis	11
2. The '514 Patent	11
3. Prosecution of the '514 Patent	13
D. Claim Construction (37 C.F.R. §§ 42.100(b), 42.104(b)(3)).....	17
E. Scope and Content of the Prior Art	18
1. January 2006 Biogen Press Release.....	18
2. Schimrigk 2004 Abstract	19
3. Kappos 2006	20
4. WO '342.....	21
5. Clinical Trials.....	23
6. Joshi '999	24
7. ICH.....	25

;

TABLE OF CONTENTS
(continued)

	Page
8. Prior Art Informing the General Knowledge of Ordinarily-Skilled Artisans	25
F. Summary of Petitioner’s Obviousness Positions	26
1. Law of Obviousness.....	26
2. The Use of DMF to Treat Autoimmune Diseases, Such As MS, Was Well Known in the Art	27
3. Skilled Artisans Would Have Been Motivated to Use 480 mg/day of DMF to Treat MS with a Reasonable Expectation of Success	29
G. Ground 1: Claims 1-20 Are Unpatentable As Obvious Over the January 2006 Biogen Press Release in View of the Schimrigk 2004 Abstract	34
1. Independent Claims 1, 11, 15, and 20 are Obvious Over the January 2006 Biogen Press Release in View of the Schimrigk 2004 Abstract	35
2. The Dependent Claims of the ’514 Patent are Obvious Over the January 2006 Biogen Press Release in View of the Schimrigk 2004 Abstract	39
H. Ground 2: Claims 1-20 Are Unpatentable As Obvious over Kappos 2006 in view of the Schimrigk 2004 Abstract	44
1. Independent Claims 1, 11, 15, and 20 are Obvious over Kappos 2006 in view of the Schimrigk 2004 Abstract.....	44
2. The Dependent Claims are Obvious over Kappos 2006 Press Release in view of the Schimrigk 2004 Abstract	48
I. Ground 3: Claims 1-20 Are Unpatentable As Obvious over Kappos 2006 in View of WO ’342	48
1. Independent Claims 1, 11, 15, and 20 are Obvious over Kappos 2006 in view of WO ’342	48
2. The Dependent Claims are Obvious over Kappos 2006 in View of WO ’342.....	50

::

TABLE OF CONTENTS
(continued)

	Page
J. Ground 4: Claims 1-20 are Unpatentable as Obvious Over Kappos 2006, Clinical Trials, Joshi '999, and ICH	50
1. Independent Claims 1, 11, 15, and 20 are obvious over Kappos 2006, Clinical Trials, Joshi '999, and ICH.....	50
2. The Dependent Claims are Obvious Over Kappos 2006, Clinical Trials, Joshi '999, and ICH	53
K. Any Purported Secondary Considerations Fail to Overcome Prima Facie Obviousness	53
1. The Methods Recited in the '514 Patent Produced No Unexpected Results.....	54
2. The '514 Patent Satisfied No Long-Felt But Unmet Need.....	60
3. Industry Praise Does Not Overcome Prima Facie Obviousness	60
L. This Petition Should Not Be Denied Institution under § 325(d)	61
VII. CONCLUSION.....	66

TABLE OF AUTHORITIES

	Page
CASES	
<i>Becton, Dickinson and Co. v. B. Braun Melsungen AG</i> , IPR2017-01586, Decision, Paper No. 8.....	63
<i>Becton, Dickson and Co.</i> , IPR2017-01586, Paper 8.....	63
<i>Boehringer Ingelheim Pharms., Inc. v. Genetech, Inc.</i> , IPR2017-02031, 2018 WL 1605267 (PTAB Mar. 29, 2018).....	65
<i>Cuozzo Speed Techs., LLC v. Lee</i> , 136 S. Ct. 2131 (2016).....	17
<i>Enova Tech. Corp. v. Seagate Tech. (US) Holdings Inc.</i> , 706 F. App'x 987 (Fed. Cir. 2017).....	61
<i>Galderma Labs., L.P. v. Tolmar, Inc.</i> , 737 F.3d 731 (Fed. Cir. 2013).....	60
<i>General Plastic Indus. Co. v. Canon Kabushiki Kaisha</i> , IPR2016-01357, Paper 19.....	6
<i>In re Am. Acad. of Sci. Tech. Ctr.</i> , 367 F.3d 1359 (Fed. Cir. 2004).....	17
<i>In re Boesch</i> , 617 F.2d 272 (C.C.P.A. 1980).....	27
<i>KSR Int'l Co. v. Teleflex Inc.</i> , 550 U.S. 398 (2007).....	27
<i>Merck Sharp & Dohme Corp. v. Pfizer Inc.</i> , IPR2017-02138, 2018 WL 1475743 (PTAB Mar. 22, 2018).....	64
<i>Pfizer, Inc. v. Apotex, Inc.</i> , 480 F.3d 1348 (Fed. Cir. 2007).....	53

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.